Novel autoantibody panel for idiopathic retroperitoneal fibrosis and diagnostic and monitoring applications thereof

By detecting a novel combination of autoantibodies for idiopathic retroperitoneal fibrosis, the lack of specific biomarkers for iRPF diagnosis has been addressed, enabling early and accurate diagnosis and monitoring of disease activity, reducing misdiagnosis rates and improving patient prognosis.

CN122109544APending Publication Date: 2026-05-29RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Filing Date
2026-01-29
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current technologies lack specific biomarkers for the diagnosis of idiopathic retroperitoneal fibrosis (iRPF), making it difficult to distinguish from retroperitoneal sarcoma (RPS) and other autoimmune diseases. Imaging examinations are costly and cannot effectively monitor disease progression and kidney damage, leading to misdiagnosis and delayed treatment.

Method used

A novel combination of autoantibodies is provided, including anti-TPM1, C1D, NPM1, IL-1A antibodies and their IgG4 subtypes. These antibodies can be detected by methods such as enzyme-linked immunosorbent assay (ELISA) and dot immunoblotting to achieve early and accurate diagnosis of iRPF, monitoring of disease activity, and assessment of kidney damage.

Benefits of technology

It improves the diagnostic specificity of iRPF, reduces the misdiagnosis rate, enables early intervention, reduces complications of renal failure, guides the adjustment of treatment plans, and is easy to operate and promote in clinical laboratories.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122109544A_ABST
    Figure CN122109544A_ABST
Patent Text Reader

Abstract

The application discloses a novel autoantibody combination for idiopathic retroperitoneal fibrosis and diagnostic and monitoring applications thereof. The application screens and verifies five iRPF-specific autoantibodies, including anti-RBPJ antibody, anti-TPM1 antibody, anti-C1D antibody, anti-NPM1 antibody, anti-IL-1A antibody, and IgG4 subtypes of the above antibodies; the autoantibodies are significantly increased in iRPF patients and have a medium and above ability to identify iRPF, wherein the anti-C1D antibody can effectively distinguish iRPF from RPS; and the anti-TPM1, NPM1 and RBPJ antibodies can also be used for disease activity monitoring. The screened autoantibodies directly reflect the autoimmune nature of iRPF, have higher specificity than existing laboratory indicators, can be detected by conventional laboratory equipment, have low cost and good promotion, and have good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art